Decent news announced today:
Departments of Urology and Oncology Approve Protocol for OncBioMune's Phase 2/3 Trial of ProscaVax for Prostate Cancer in Mexico
OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, is pleased to announce the receipt of acknowledgement and authorization to perform the protocol proposed for the Phase 2/3 clinical trial of ProscaVax from the Department of Urology of the High Specialty Hospital IMSS Siglo XXI ("HSH IMSS") in Mexico. The clinical study is being sponsored by OncBioMune Mexico S.A. de C.V., a joint venture between the Company and its planned acquisition target, Vitel Laboratorios S.A. de C.V., and being conducted at HSH IMSS, which is considered the foremost government hospital in Mexico.
In the study, ProscaVax, OncBioMune's lead experimental therapeutic cancer vaccine, will be evaluated for safety and efficacy in prostate specific antigen (PSA) recurrent prostate cancer in hormone-naïve and hormone-independent patients.
The authorization from the Department of Urology follows a recently received authorization to perform the protocol from the Department of Oncology at HSH IMSS.
"Receiving authorization from both departments was not necessary and is a tremendous vote of confidence that directors of each unit are interested in participating in the clinical trial," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "We now have the full weight and expertise of each department to oversee the study, support gathering patients for enrollment and all the equipment required to complete the protocol in hand. This is an incredible asset for us and should help ensure an efficiently run trial."
